70191-71-8

Basic information

• Product Name: (6aS,12aS)-9-hydroxy-2,3-dimethoxy-8-(3-methylbut-2-en-1-yl)-6a,12a-dihydrochromeno[3,4-b]chromen-12(6H)-one
• CAS NO: 70191-71-8
• Molecular Formula: C₂₃H₂₄O₆
• Molecular Weight: 396.4331
• Mol File: 70191-71-8.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 582.9°C at 760 mmHg
• Flash Point: 202.3°C
• Density: 1.243g/cm³
• Vapor Pressure: 3.47E-14mmHg at 25°C
• Refractive Index: 1.59
• CAS DataBase Reference: (6aS,12aS)-9-hydroxy-2,3-dimethoxy-8-(3-methylbut-2-en-1-yl)-6a,12a-dihydrochromeno[3,4-b]chromen-12(6H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: (6aS,12aS)-9-hydroxy-2,3-dimethoxy-8-(3-methylbut-2-en-1-yl)-6a,12a-dihydrochromeno[3,4-b]chromen-12(6H)-one(70191-71-8)
• EPA Substance Registry System: (6aS,12aS)-9-hydroxy-2,3-dimethoxy-8-(3-methylbut-2-en-1-yl)-6a,12a-dihydrochromeno[3,4-b]chromen-12(6H)-one(70191-71-8)

Safety Data

• Hazardous Substances Data: 70191-71-8(Hazardous Substances Data)

Upstream product

• 58277-58-0 (6aS,12aS,5’R)-rotenone hydrobromide 
• 70191-70-7 4'-bromorot-2'-enonic acid 
• 83-79-4 rotenone 
• 23355-70-6 (6aS,12aS,5'R)-rotenone enol acetate 
• 4208-09-7 amorphigenin 
• 141882-80-6 amorphigenin acetate 6'-norketone enol acetate 
• 142050-36-0 amorphigenin acetate enol acetate 
• 81924-61-0 Acetic acid 2-((2R,6aS,12aS)-8,9-dimethoxy-6-oxo-1,2,6,6a,12,12a-hexahydro-chromeno[3,4-b]furo[2,3-h]chromen-2-yl)-2-oxo-ethyl ester 
• 4208-10-0 amorphigenin acetate 
• 23295-59-2 rotenone 6'-norketone enol acetate 
• 15130-81-1 (6aS,12aS,5′R)-rotenone-6′-norketone 
• 124571-93-3 (6aS,12S,12aS,5'S)-12-deoxo-12-hydroxy-5'-phenylthio-4',5'-dihydrodeguelin 
• 34487-52-0 (2R,6aS,12aS)-8-hydroxy-9-methoxy-2-(prop-1-en-2-yl)-1,2,12,12a- tetrahydrochromeno[3,4-b]furo[2,3-h]chromen-6(6aH)-one 
• 124571-94-4 (6aS,12S,12aR)-2,3-Dimethoxy-8-(3-methyl-but-2-enyl)-6,6a,12,12a-tetrahydro-chromeno[3,4-b]chromene-9,12-diol 

Downstream Products

• 49855-12-1 (+/-)-rotenonoic acid 
• 70191-72-9 (6aS,12aS,5'R)-5'-(phenylseleno)dihydrodeguelin 
• 70145-45-8 (6aS,12aS,5'S)-5'-(phenylseleno)dihydrodeguelin 
• 522-17-8 (-)-deguelin 
• 522-17-8 cis-deguelin 
• 1386350-22-6 9-benzyloxy-2,3-dimethoxy-8-(3-methyl-but-2-enyl)-6a,12a-dihydro-6H-chromeno[3,4-b]chromen-12-one 
• 1386350-03-3 (7S,7aR,3aS)-7-benzyloxy-9,10-dimethoxy-3,3-dimethyl-7,7a,13,13a-tetrahydro-3H-chromeno[3,4-b]pyrano[2,3-h]chromene 
• 1386350-15-7 (7aR,13aS)-9,10-dimethoxy-3,3-dimethyl-13,13a-dihydro-3H-chromeno[3,4-b]pyrano[2,3-h]chro men-7(7aH)-one O-benzyloxime 
• 76-80-2 tephrosin 

Relevant articles and documents

-

-

Stereocontrolled semi-syntheses of deguelin and tephrosin

We describe stereocontrolled semi-syntheses of deguelin and tephrosin, anti-cancer rotenoids isolated from Tephrosia vogelii. Firstly, we present a new two-step transformation of rotenone into rot-2′-enonic acid via a zinc-mediated ring opening of rotenone hydrobromide. Secondly, following conversion of rot-2′-enonic acid into deguelin, a chromium-mediated hydroxylation provides tephrosin as a single diastereoisomer. An étard-like reaction mechanism is proposed to account for the stereochemical outcome. Our syntheses of deguelin and tephrosin are operationally simple, scalable and high yielding, offering considerable advantages over previous methods.

NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to a novel compound inhibiting Hsp 90 and to a pharmaceutical composition including same as an active ingredient. Compounds of formula 1 and formula 2 according to the present invention inhibit the accumulation of HIF-1α protein, which is an Hsp90 client protein, by suppressing Hsp90 expression, and effectively inhibit the activity of vascular endothelial growth factor (VEGF). Furthermore, said compounds have low cytotoxicity and can thus be used as an active ingredient for the treatment of diabetic retinopathy and arthritis.

Contrast agents for myocardial perfusion imaging

The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.